# A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

> **NCT01375842** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 661 (actual)

## Conditions studied

- Tumors
- Hematologic Malignancies

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT01375842
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-21
- **Primary completion:** 2018-09-30
- **Final completion:** 2018-09-30
- **Target enrollment:** 661 (ACTUAL)
- **Last updated:** 2018-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01375842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01375842, "A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01375842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*